IAM
AVBP icon

Infinitum Asset Management’s ArriVent BioPharma AVBP Stock Holding History

Infinitum Asset Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$95.7M Buy
4,148,923
+25,000
+0.6% +$565K 11.95% 2
2025
Q4 		$83M Buy
4,123,923
+255,000
+7% +$5.31M 12.28% 2
2025
Q3 		$71.4M Buy
3,868,923
+450,000
+13% +$8.84M 13.13% 2
2025
Q2 		$74.4M Buy
3,418,923
+1,352,685
+65% +$28.1M 16.48% 2
2025
Q1 		$38.2M Buy
2,066,238
+422,315
+26% +$10.3M 12.22% 2
2024
Q4 		$43.8M Buy
+1,643,923
New +$47.2M 23.15% 2

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GCGM
General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return

Infinitum Asset Management's AVBP Position: Q1 2026 in Review

Infinitum Asset Management increased its ArriVent BioPharma (AVBP) stake by 0.61% in Q1 2026, buying an estimated $565K and bringing the position to 4,148,923 shares worth $95.7M. The position accounts for 11.95% of the portfolio, ranked #2.

Infinitum Asset Management first reported a position in AVBP in Q4 2024 and has held it in 6 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Infinitum Asset Management held 4,148,923 shares of ArriVent BioPharma worth $95.7M as of Q1 2026.
  • Infinitum Asset Management bought 25,000 ArriVent BioPharma shares in Q1 2026, an estimated $565K.
  • ArriVent BioPharma made up 11.95% of Infinitum Asset Management's portfolio in Q1 2026, its #2 holding.
  • Infinitum Asset Management first reported a position in ArriVent BioPharma in Q4 2024 and has held it in 6 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Infinitum Asset Management's 13F filing for Q1 2026, filed 15 May 2026.